Eight Companies Approved for
Promotion of Domestic Manufacturing of Critical Key Starting Materials (KSMs)/
Drug Intermediates and Active Pharmaceutical Ingredients (APIs) under PLI
Scheme
The Indian pharmaceutical industry is the 3rd
largest in the world by volume. It has high market presence in several advanced
economies such as the US and EU. The industry is well known for its production of
affordable medicines, particularly in the generics space. However, the country is
significantly dependent on the import of basic raw materials, viz., Bulk Drugs that
are used to produce medicines. In some specific bulk drugs, the import dependence
is 80 to 100%.
With an objective to attain self-reliance and reduce
import dependence in these critical Bulk Drugs - Key Starting Materials (KSMs)/
Drug Intermediates and Active Pharmaceutical Ingredients (APIs) in the country,
the Department of Pharmaceuticals had launched a Production Linked Incentive (PLI)
Scheme for promotion of their domestic manufacturing by setting up greenfield plants
with minimum domestic value addition in four different Target Segments (In Two Fermentation
based - at least 90% and in the Two Chemical Synthesis based – at least 70% ) for
41 products with a total outlay of Rs. 6,940 cr. for the
period 2020-21 to 2029-30.
In total, 215 applications were received for the
36 products spread across the 4 Target Segments. Out of which, total 42 applications
were approved by the Government with a total Committed Investment of Rs. 4,347.26 Crore and expected Employment Generation of around
8,792 persons.
Since few slots remained unfilled for certain products,
applications were invited again with the last date of submission as 31.08.2021.
Total 24 applications were received.
In the 9th Meeting of the Empowered
Committee held on 25.11.2021, after considering all the applications received, the
applications of following companies, which fulfill the prescribed criteria laid
down in scheme guidelines have been approved, as under:
|
S.No. |
Name
of approved Applicant |
Name
of Eligible Product |
Committed
Production Capacity(in MT) |
Committed
Investment (in Rs. crores) |
|
Target Segment III – Key Chemical Synthesis Based KSMs/Drug
Intermediates |
|
|||
|
1 |
M/s AlkimiaPharma-Chem Pvt. Ltd.
(APCPL) |
1,1 Cyclohexane Diacetic Acid (CDA)’ |
1500 |
22.47 |
|
Target Segment IV – Other Chemical Synthesis Based KSMs/Drug
Intermediates/APIs |
|
|||
|
1 |
M/s Globela Industries Pvt. Ltd.
(GIPL) |
Ofloxacin |
100 |
22.00 |
|
2 |
M/s Globela Industries Pvt. Limited
(GIPL) |
Norfloxacin |
60 |
15.51 |
|
3 |
M/s Alta Laboratories Limited
(ALL) |
Aspirin |
2250 |
12.44 |
|
4 |
M/s AviranPharmachem Private Limited
(APPL) |
Artesunate |
20 |
5.69 |
|
5 |
M/s K P Manish Global Ingredients Pvt. Ltd. (KPMGIPL) |
|
80 |
15.00 |
|
6 |
M/s SudarshanPharma Industries Ltd.
(SPIL) |
Vitamin B6’ |
35 |
27.00 |
|
7 |
M/s Honour Lab Ltd. (HLL) |
|
140 |
31.00 |
The setting up of these 8 plants will lead to total
committed investment of about Rs.151.12 crore by the companies and employment generation
of about 1,951. The commercial production of these plants is projected to commence
from 1st April, 2023 onwards.
With this, the total applications
approved under both rounds aggregate to 50 applicants with committed
investment of Rs 4,498.38 crore and employment generation
of about 10,743. Setting up of these plants will make the country self-reliant to
a large extent in respect of these Bulk drugs.